;PMID: 7816250
;source_file_639.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..121] = [t:49..121]
;2)section:[e:125..172] = [t:125..172]
;3)section:[e:176..253] = [t:176..253]
;4)sentence:[e:257..446] = [t:257..446]
;5)sentence:[e:447..668] = [t:447..668]
;6)sentence:[e:669..834] = [t:669..834]
;7)sentence:[e:835..1004] = [t:835..1004]
;8)sentence:[e:1005..1218] = [t:1005..1218]
;9)sentence:[e:1219..1378] = [t:1219..1378]
;10)sentence:[e:1379..1507] = [t:1379..1507]
;11)section:[e:1511..1555] = [t:1511..1555]

;section 0 Span:0..43
;Nephrol Dial Transplant. 1994;9(10):1390-4.
(SEC
  (FRAG (NNP:[0..7] Nephrol) (NNP:[8..12] Dial) (NNP:[13..23] Transplant)
        (.:[23..24] .) (CD:[25..30] 1994;) (CD:[30..31] 9) (NN:[31..32] -LRB-)
        (NN:[32..34] 10) (NN:[34..35] -RRB-) (::[35..36] :) (CD:[36..39] 139)
        (CD:[39..42] 0-4) (.:[42..43] .)))

;sentence 1 Span:49..121
;Inhibition of growth by calcitriol in a proximal tubular cell line (OK).
;[73..83]:substance:"calcitriol"
(SENT
  (NP-HLN
    (NP (NN:[49..59] Inhibition))
    (PP (IN:[60..62] of)
      (NP (NN:[63..69] growth)))
    (PP (IN:[70..72] by)
      (NP (NN:[73..83] calcitriol)))
    (PP-LOC (IN:[84..86] in)
      (NP
        (NP (DT:[87..88] a)
          (ADJP (JJ:[89..97] proximal) (JJ:[98..105] tubular))
          (NN:[106..110] cell) (NN:[111..115] line))
        (PRN (-LRB-:[116..117] -LRB-)
          (NP (NN:[117..119] OK))
          (-RRB-:[119..120] -RRB-))))
    (.:[120..121] .)))

;section 2 Span:125..172
;Weih M, Orth S, Weinreich T, Reichel H, Ritz E.
(SEC
  (FRAG (NNP:[125..129] Weih) (NNP:[130..132] M,) (NNP:[133..137] Orth)
        (NNP:[138..139] S) (,:[139..140] ,) (NNP:[141..150] Weinreich)
        (NNP:[151..152] T) (,:[152..153] ,) (NNP:[154..161] Reichel)
        (NNP:[162..164] H,) (NNP:[165..169] Ritz) (NNP:[170..172] E.)))

;section 3 Span:176..253
;Department Internal Medicine, Ruperto Carola University, Heidelberg,
;Germany.
(SEC
  (FRAG (NNP:[176..186] Department) (IN:[187..195] Internal)
        (NNP:[196..204] Medicine) (,:[204..205] ,) (NNP:[206..213] Ruperto)
        (NNP:[214..220] Carola) (NNP:[221..231] University) (,:[231..232] ,)
        (NNP:[233..243] Heidelberg) (,:[243..244] ,) (NNP:[245..252] Germany)
        (.:[252..253] .)))

;sentence 4 Span:257..446
;Calcitriol has been shown to inhibit (i) cell proliferation of renal
;carcinoma  cell lines and of cultured adult human mesangial cells in vitro,
;and (ii) renal  compensatory growth in vivo.
;[257..267]:substance:"Calcitriol"
(SENT
  (S
    (NP-SBJ-4 (NN:[257..267] Calcitriol))
    (VP (VBZ:[268..271] has)
      (VP (VBN:[272..276] been)
        (VP (VBN:[277..282] shown)
          (S
            (NP-SBJ-4 (-NONE-:[282..282] *))
            (VP (TO:[283..285] to)
              (VP
                (VP (VB:[286..293] inhibit)
                  (NP=2
                    (LST (LS:[294..297] -LRB-i-RRB-))
                    (NP (NN:[298..302] cell) (NN:[303..316] proliferation))
                    (PP
                      (PP (IN:[317..319] of)
                        (NP (JJ:[320..325] renal) (NN:[326..335] carcinoma)
                            (NN:[337..341] cell) (NNS:[342..347] lines)))
                      (CC:[348..351] and)
                      (PP (IN:[352..354] of)
                        (NP (JJ:[355..363] cultured)
                          (ADJP (JJ:[364..369] adult) (JJ:[370..375] human))
                          (JJ:[376..385] mesangial) (NNS:[386..391] cells)))))
                  (ADVP=3 (FW:[392..394] in) (FW:[395..400] vitro)))
                (,:[400..401] ,) (CC:[402..405] and)
                (VP
                  (NP=2
                    (LST (LS:[406..410] -LRB-ii-RRB-))
                    (JJ:[411..416] renal) (JJ:[418..430] compensatory)
                     (NN:[431..437] growth))
                  (ADVP=3 (FW:[438..440] in) (FW:[441..445] vivo)))))))))
    (.:[445..446] .)))

;sentence 5 Span:447..668
;In the present study we examined the effects of  calcitriol on DNA synthesis
;and cell replication in an immortalized cell line  showing the phenotypic
;characteristics of proximal tubular cells (opossum  kidney, OK cells).
;[496..506]:substance:"calcitriol"
;[510..513]:substance:"DNA"
(SENT
  (S
    (PP-LOC (IN:[447..449] In)
      (NP (DT:[450..453] the) (JJ:[454..461] present) (NN:[462..467] study)))
    (NP-SBJ (PRP:[468..470] we))
    (VP (VBD:[471..479] examined)
      (NP
        (NP (DT:[480..483] the) (NNS:[484..491] effects))
        (PP (IN:[492..494] of)
          (NP (NN:[496..506] calcitriol)))
        (PP (IN:[507..509] on)
          (NP
            (NP (NN:[510..513] DNA) (NN:[514..523] synthesis))
            (CC:[524..527] and)
            (NP (NN:[528..532] cell) (NN:[533..544] replication)))))
      (PP-LOC (IN:[545..547] in)
        (NP
          (NP (DT:[548..550] an) (JJ:[551..563] immortalized)
              (NN:[564..568] cell) (NN:[569..573] line))
          (VP (VBG:[575..582] showing)
            (NP
              (NP (DT:[583..586] the) (JJ:[587..597] phenotypic)
                  (NNS:[598..613] characteristics))
              (PP (IN:[614..616] of)
                (NP
                  (ADJP (JJ:[617..625] proximal) (JJ:[626..633] tubular))
                  (NNS:[634..639] cells)
                  (PRN (-LRB-:[640..641] -LRB-)
                    (NP
                      (NP (NN:[641..648] opossum) (NN:[650..656] kidney))
                      (,:[656..657] ,)
                      (NP (NN:[658..660] OK) (NNS:[661..666] cells)))
                    (-RRB-:[666..667] -RRB-)))))))))
    (.:[667..668] .)))

;sentence 6 Span:669..834
;The viability of OK cells was not affected by calcitriol  (Trypan-blue
;exclusion, LDH and K+ release), but the cells did not convert  3H-25(OH)2D3
;to 3H-1,25(OH)2D3.
;[715..725]:substance:"calcitriol"
;[728..739]:substance:"Trypan-blue"
;[751..754]:substance:"LDH"
;[759..761]:substance:"K+"
;[803..815]:substance:"3H-25(OH)2D3"
;[819..833]:substance:"3H-1,25(OH)2D3"
(SENT
  (S
    (S
      (NP-SBJ-2
        (NP (DT:[669..672] The) (NN:[673..682] viability))
        (PP (IN:[683..685] of)
          (NP (NN:[686..688] OK) (NNS:[689..694] cells))))
      (VP (VBD:[695..698] was) (RB:[699..702] not)
        (VP (VBN:[703..711] affected)
          (NP-2 (-NONE-:[711..711] *))
          (PP (IN:[712..714] by)
            (NP-LGS
              (NP (NN:[715..725] calcitriol))
              (PRN (-LRB-:[727..728] -LRB-)
                (NP
                  (NP
                    (ADJP (NN:[728..734] Trypan) (HYPH:[734..735] -)
                          (JJ:[735..739] blue))
                    (NN:[740..749] exclusion))
                  (,:[749..750] ,)
                  (NP (NN:[751..754] LDH))
                  (CC:[755..758] and)
                  (NP
                    (NML (NN:[759..760] K) (SYM:[760..761] +))
                    (NN:[762..769] release)))
                (-RRB-:[769..770] -RRB-)))))))
    (,:[770..771] ,) (CC:[772..775] but)
    (S
      (NP-SBJ (DT:[776..779] the) (NNS:[780..785] cells))
      (VP (VBD:[786..789] did) (RB:[790..793] not)
        (VP (VB:[794..801] convert)
          (NP (NN:[803..815] 3H-25-LRB-OH-RRB-2D3))
          (PP (TO:[816..818] to)
            (NP (NN:[819..833] 3H-1,25-LRB-OH-RRB-2D3))))))
    (.:[833..834] .)))

;sentence 7 Span:835..1004
;In the log growth phase, calcitriol (but not  alternative vitamin D
;metabolites) caused dose-dependent (10(-12) to 10(-6) M)  inhibition of
;radiothymidine incorporation.
;[860..870]:substance:"calcitriol"
;[893..914]:substance:"vitamin D metabolites"
;[939..956]:quantitative-value:"10(-12) to 10(-6)"
;[957..958]:quantitative-units:"M"
;[975..989]:substance:"radiothymidine"
(SENT
  (S
    (PP-LOC (IN:[835..837] In)
      (NP (DT:[838..841] the)
        (NML (NN:[842..845] log) (NN:[846..852] growth))
        (NN:[853..858] phase)))
    (,:[858..859] ,)
    (NP-SBJ
      (NP (NN:[860..870] calcitriol))
      (PRN (-LRB-:[871..872] -LRB-)
        (FRAG
          (CONJP (CC:[872..875] but) (RB:[876..879] not))
          (NP (JJ:[881..892] alternative)
            
            (NML (NN:[893..900] vitamin) (NN:[901..902] D))
            (NNS:[903..914] metabolites)))
        (-RRB-:[914..915] -RRB-)))
    (VP (VBD:[916..922] caused)
      (NP
        (NP
          (ADJP (NN:[923..927] dose) (HYPH:[927..928] -)
                (JJ:[928..937] dependent)
            (PRN (-LRB-:[938..939] -LRB-)
              (NP
                (QP (CD:[939..946] 10-LRB--12-RRB-) (TO:[947..949] to)
                    (CD:[950..956] 10-LRB--6-RRB-))
                (NN:[957..958] M))
              (-RRB-:[958..959] -RRB-)))
          (NN:[961..971] inhibition))
        (PP (IN:[972..974] of)
          (NP (NN:[975..989] radiothymidine) (NN:[990..1003] incorporation)))))
    (.:[1003..1004] .)))

;sentence 8 Span:1005..1218
;Inhibition was calcium dependent,  i.e. it was more pronounced at the lower
;nominal calcium concentration in tissue  culture media (0.9 versus 1.8
;mmol/l) and amplified by coincubation with  nifedipine (1 microM).
;[1020..1027]:substance:"calcium"
;[1089..1096]:substance:"calcium"
;[1137..1140]:quantitative-value:"0.9"
;[1148..1151]:quantitative-value:"1.8"
;[1152..1158]:quantitative-units:"mmol/l"
;[1196..1206]:substance:"nifedipine"
;[1208..1209]:quantitative-value:"1"
;[1210..1216]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ (NN:[1005..1015] Inhibition))
    (VP (VBD:[1016..1019] was)
      (NP-PRD (NN:[1020..1027] calcium) (JJ:[1028..1037] dependent))
      (,:[1037..1038] ,)
      (S-ADV
        (ADVP (FW:[1040..1044] i.e.))
        (NP-SBJ-1 (PRP:[1045..1047] it))
        (VP (VBD:[1048..1051] was)
          (UCP
            (ADJP-PRD (RBR:[1052..1056] more) (JJ:[1057..1067] pronounced)
              (PP (IN:[1068..1070] at)
                (NP (DT:[1071..1074] the) (JJR:[1075..1080] lower)
                    (JJ:[1081..1088] nominal) (NN:[1089..1096] calcium)
                    (NN:[1097..1110] concentration)))
              (PP (IN:[1111..1113] in)
                (NP
                  (NML (NN:[1114..1120] tissue) (NN:[1122..1129] culture))
                  (NNS:[1130..1135] media)))
              (PRN (-LRB-:[1136..1137] -LRB-)
                (NP
                  (NP
                    (NP (CD:[1137..1140] 0.9))
                    (PP (IN:[1141..1147] versus)
                      (NP (CD:[1148..1151] 1.8) (NN:[1152..1156] mmol))))
                  (PP (SYM:[1156..1157] /)
                    (NP (NN:[1157..1158] l))))
                (-RRB-:[1158..1159] -RRB-)))
            (CC:[1160..1163] and)
            (VP (VBN:[1164..1173] amplified)
              (NP-1 (-NONE-:[1173..1173] *))
              (PP-MNR (IN:[1174..1176] by)
                (NP
                  (NP (NN:[1177..1189] coincubation))
                  (PP (IN:[1190..1194] with)
                    (NP (NN:[1196..1206] nifedipine)
                      (PRN (-LRB-:[1207..1208] -LRB-)
                        (NP (CD:[1208..1209] 1) (NN:[1210..1216] microM))
                        (-RRB-:[1216..1217] -RRB-)))))))))))
    (.:[1217..1218] .)))

;sentence 9 Span:1219..1378
;Inhibition of DNA synthesis was paralleled by inhibition  of cell replication
;(growth curve) under basal conditions and after stimulation  with EGF (10
;ng/ml).
;[1233..1236]:substance:"DNA"
;[1363..1366]:substance:"EGF"
;[1368..1370]:quantitative-value:"10"
;[1371..1376]:quantitative-units:"ng/ml"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1219..1229] Inhibition))
      (PP (IN:[1230..1232] of)
        (NP (NN:[1233..1236] DNA) (NN:[1237..1246] synthesis))))
    (VP (VBD:[1247..1250] was)
      (VP (VBN:[1251..1261] paralleled)
        (NP-1 (-NONE-:[1261..1261] *))
        (PP (IN:[1262..1264] by)
          (NP-LGS
            (NP (NN:[1265..1275] inhibition))
            (PP (IN:[1277..1279] of)
              (NP (NN:[1280..1284] cell) (NN:[1285..1296] replication)))
            (PRN (-LRB-:[1297..1298] -LRB-)
              (NP (NN:[1298..1304] growth) (NN:[1305..1310] curve))
              (-RRB-:[1310..1311] -RRB-))))
        (PP
          (PP (IN:[1312..1317] under)
            (NP (JJ:[1318..1323] basal) (NNS:[1324..1334] conditions)))
          (CC:[1335..1338] and)
          (PP-TMP (IN:[1339..1344] after)
            (NP
              (NP (NN:[1345..1356] stimulation))
              (PP (IN:[1358..1362] with)
                (NP
                  (NP (NN:[1363..1366] EGF))
                  (PRN (-LRB-:[1367..1368] -LRB-)
                    (NP
                      (NP (CD:[1368..1370] 10) (NN:[1371..1373] ng))
                      (PP (SYM:[1373..1374] /)
                        (NP (NN:[1374..1376] ml))))
                    (-RRB-:[1376..1377] -RRB-)))))))))
    (.:[1377..1378] .)))

;sentence 10 Span:1379..1507
;In conclusion, calcitriol inhibits proliferation of  proximal tubular cells
;which normally express 1-alpha-hydroxylase activity.
;[1394..1404]:substance:"calcitriol"
;[1478..1497]:substance:"1-alpha-hydroxylase"
(SENT
  (S
    (PP (IN:[1379..1381] In)
      (NP (NN:[1382..1392] conclusion)))
    (,:[1392..1393] ,)
    (NP-SBJ (NN:[1394..1404] calcitriol))
    (VP (VBZ:[1405..1413] inhibits)
      (NP
        (NP (NN:[1414..1427] proliferation))
        (PP (IN:[1428..1430] of)
          (NP
            (NP
              (ADJP (JJ:[1432..1440] proximal) (JJ:[1441..1448] tubular))
              (NNS:[1449..1454] cells))
            (SBAR
              (WHNP-1 (WDT:[1455..1460] which))
              (S
                (NP-SBJ-1 (-NONE-:[1460..1460] *T*))
                (ADVP (RB:[1461..1469] normally))
                (VP (VBP:[1470..1477] express)
                  (NP (NN:[1478..1497] 1-alpha-hydroxylase)
                      (NN:[1498..1506] activity)))))))))
    (.:[1506..1507] .)))

;section 11 Span:1511..1555
;PMID: 7816250 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1511..1515] PMID) (::[1515..1516] :) (CD:[1517..1524] 7816250)
        (NN:[1525..1526] -LSB-) (NNP:[1526..1532] PubMed) (::[1533..1534] -)
        (NN:[1535..1542] indexed) (IN:[1543..1546] for)
        (NNP:[1547..1555] MEDLINE-RSB-)))
